Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Jazz Pharmaceuticals plc is a biotechnology business based in the US. Jazz Pharmaceuticals shares (JAZZ) are listed on the NASDAQ and all prices are listed in US Dollars. Jazz Pharmaceuticals employs 1,940 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $136.76 |
|---|---|
| 52-week range | $117.64 - $189.00 |
| 50-day moving average | $130.18 |
| 200-day moving average | $151.08 |
| Wall St. target price | $201.35 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.76 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $136.76 from 2022-01-21
| 1 week (2022-01-14) | -5.23% |
|---|---|
| 1 month (2021-12-22) | 7.09% |
| 3 months (2021-10-22) | -5.58% |
| 6 months (2021-07-22) | -21.32% |
| 1 year (2021-01-22) | -18.91% |
|---|---|
| 2 years (2020-01-22) | -9.11% |
| 3 years (2019-01-22) | 6.30% |
| 5 years (2017-01-20) | 10.40% |
Valuing Jazz Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jazz Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Jazz Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.9772. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Jazz Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Jazz Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a Jazz Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.9 billion |
|---|---|
| Operating margin TTM | 23.41% |
| Gross profit TTM | $2.2 billion |
| Return on assets TTM | 4.46% |
| Return on equity TTM | -4.4% |
| Profit margin | -5.62% |
| Book value | $64.17 |
| Market capitalisation | $8.9 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Jazz Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 31.66
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Jazz Pharmaceuticals's overall score of 31.66 (as at 12/31/2018) is nothing to write home about – landing it in it in the 51st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Jazz Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.18/100
Jazz Pharmaceuticals's environmental score of 4.18 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.74/100
Jazz Pharmaceuticals's social score of 24.74 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.74/100
Jazz Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Jazz Pharmaceuticals scored a 1 out of 5 for controversy – the highest score possible, reflecting that Jazz Pharmaceuticals has managed to keep its nose clean.
Jazz Pharmaceuticals plc was last rated for ESG on: 2019-01-01.
| Total ESG score | 31.66 |
|---|---|
| Total ESG percentile | 51.04 |
| Environmental score | 4.18 |
| Environmental score percentile | 8 |
| Social score | 24.74 |
| Social score percentile | 8 |
| Governance score | 13.74 |
| Governance score percentile | 8 |
| Level of controversy | 1 |
We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $117.64 up to $189. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 0.9412. This would suggest that Jazz Pharmaceuticals's shares are less volatile than average (for this exchange).
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. ; Codiak BioSciences, Inc. ; Pfenex, Inc.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.